IR-Med Inc. (IRME) Stock Price & Analysis
IR-Med Inc. (IRME) — price $0.0021 (0.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
IR-Med Inc. · IRME
IR-Med Inc. is a medical device company focused on developing non-invasive monitoring devices. Their product pipeline includes devices for early detection of pressure injuries, diabetic foot ulcers, and middle ear infections.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.0021 |
| Change on the day | 0.00% |
| Shares traded on the day | 594 |
Price & events
Other perspectives
Council score for IR-Med (IRME): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 29, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: May 2, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On May 2, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is IR-Med (IRME), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. IR-Med Inc. (IRME) is the company analyzed here. It employs 3 people. In Q4 FY2024 it reported revenue of $26,000 and net income of -$278,000.
What do the latest results show for IR-Med (IRME)?
Short answer · as of
The most recent reported quarter, Q4 FY2024, carried revenue of $26,000. Against analyst estimates the company has EPS beat 1 of the last 7 reports.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2024 | $26,000 | -$278,000 | -$0.0039 (diluted) |
What are the financial strengths and risks for IR-Med (IRME)?
Short answer · as of
The distress and quality screens read Piotroski F 3. Trailing ratios: current ratio 0.38.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 7 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at IR-Med (IRME)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $30.90M · EPS 0.17 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q4 FY2024) was filed Apr 4, 2025 — 11 months ago.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $30.90M
- EPS estimate
- $0.17
Measured against a quoted price of $0.0021 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held IRME in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported IRME in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
IR-Med Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the IRME research dossier (written Mar 18, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What are the potential benefits of IR-Med Inc.'s products for healthcare providers?
IR-Med Inc.'s products offer several potential benefits for healthcare providers. PressureSafe can help reduce the incidence of pressure injuries, leading to lower treatment costs and improved patient comfort.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 8 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com